Skip to main content

Table 3 Summary of Tsc2-/- Subcutaneous Tumor Data (Vincristine, Asparaginase, Sunitinib, and Bevacizumab)

From: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

  Untreated Rapamycin Vincristine Combination Vincristine plus Rapamycin Asparaginase Combination Asparaginase plus Rapamycin Sunitinib Combination Sunitinib plus Rapamycin Bevacizumab Combination Bevacizumab plus Rapamycin
Number of mice (n) 8 8 8 8 8 8 8 8 8 8
Median Survival (days) 31 84.5 26 77 39.5 71 39 80 38.5 60
P value (survival) - <0.0001* NS* NS# 0.0101* NS# 0.0193* NS# 0.0131* NS#
Day 23, average tumor volume ± SEM (mm3) 1557 ± 260 352 ± 149 2289 ± 242 - - - - - - -
P Value (Day 23) - 0.0016* NS* - - - - - - -
Day 30, average tumor volume ± SEM (mm3) 2618 ± 187 545 ± 212 - 330 ± 101 1978 ± 167 441 ± 97 1886 ± 287 545 ± 114 1233 ± 366 813 ± 449
P Value (Day 30) - 0.0001* - - 0.0405* - NS* - 0.0172* -
Day 65, average tumor volume ± SEM (mm3) - 1349 ± 302 - 2050 ± 384 - 1570 ± 378 - 1643 ± 246 - 1652 ± 557
P Value (Day 65) - - - NS# - NS# - NS# - NS#
Rapamycin (IP, 3 days per week) - 8 mg/kg, 3 days per week - 8 mg/kg, 3 days per week - 8 mg/kg, 3 days per week - 8 mg/kg, 3 days per week - 8 mg/kg, 3 days per week
Vincristine (IP, weekly × 4 weeks) - - 0.5 mg/kg, weekly × 4 weeks 0.5 mg/kg, weekly × 4 weeks - - - - - -
Asparaginase (IP, Mon, Thurs × 4 weeks) - - - - 2 IU/g, Mon, Thurs × 4 weeks 2 IU/g, Mon, Thurs × 4 weeks - - - -
Sunitinib (Gavage, Mon-Fri) - -    - - 80 mg/kg, Mon- Fri 80 mg/kg, Mon- Fri - -
Bevacizumab (IP, once/2 weeks) - - - - - - - - 5 mg/kg, once/2 weeks 5 mg/kg, once/2 weeks
  1. * compared to untreated
  2. # compared to rapamycin treated
  3. NS, not significant